Don’t let corporate actors hijack the pharmacare committeeNovember 7, 2024November 7, 2024by Nikolas Barry-ShawAnalysis
Poilievre’s dubious ideas about pharmacare—brought to you by Big PharmaOctober 21, 2024October 24, 2024by Nikolas Barry-ShawAnalysis
The Pharmacare Act has passed third reading. Here’s what comes next.June 4, 2024July 10, 2024by Nikolas Barry-ShawAnalysis
Corporate lobbyists dominate hearings for Pharmacare ActMay 27, 2024May 27, 2024by Nikolas Barry-ShawAnalysis
The Conference Board of Canada: Putting a respectable face on Big Pharma spinMay 8, 2024May 13, 2024by Nikolas Barry-ShawAnalysis
Big Pharma’s ‘Intellectual Echo Chambers’ and the fight to lower drug prices in Canada May 3, 2024May 4, 2024by Nikolas Barry-ShawAnalysis
Federal budget a missed opportunity to secure pharmacare’s futureApril 25, 2024April 29, 2024by Nikolas Barry-ShawAnalysis
What we know about the Liberal-NDP pharmacare deal so farFebruary 26, 2024October 7, 2024by Nikolas Barry-ShawAnalysis
